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Abstract: Plastid transformation technology is set to become a major player in the production of human therapeutic
proteins. Protein expression levels that can be achieved in plant plastids are hundreds of times greater than the expression
levels generally obtained via nuclear transformation. Plastids can produce human proteins that are properly folded and are
biologically active. Effective protein purification strategies and strategies that can achieve inducible plastid gene
expression are being developed within the system. Plastid transformation technology has been extended to edible plant
species, which could minimize down-stream processing costs and raises the possibility of “edible protein therapies”. The
system is limited by the fact that plastid-produced proteins are not glycosylated and that, at the moment, it can be difficult
to predict protein stability within the plastid. The high level of protein expression that can be obtained in plastids could
make it possible to produce high-value therapeutic proteins in plants on a scale that could be accommodated in contained
glasshouse facilities and still be economically viable. Growing plastid-transformed plants under contained conditions, and
coupled with the level of bio-safety conferred by maternal inheritance of plastid transgenes, would address many of the
social and environmental concerns relating to plant based production of human therapeutic proteins.
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INTRODUCTION
Plant biotechnology has revolutionized the concept of
plants both as traditional production systems and as
production systems for novel proteins. Initial efforts of plant
biotechnologists focused on using plant transformation to
address the more conventional concerns of crop scientists
and were mainly directed towards increasing crop yield (e.g.
engineered insect or herbicide resistance [1, 2]) or extending
post-harvest shelf life [3, 4]. More recent applications of
plant biotechnology have focused on developing plants as
bioreactors for the production of novel proteins with
potential biomedical applications, including sub-unit
vaccines, antibodies, and a range of other therapeutic
compounds. This shift in emphasis was prompted by the
need to produce therapeutic molecules free from human or
animal pathogens, by a realization of the economy of scale
offered by plant production systems relative to more
conventional recombinant protein production systems, and
by the need to demonstrate to a skeptical public that plant
biotechnology has more to offer than genetically modified
(GM) food destined for the supermarket shelf. The aim of
this article is to review plant based production of human
therapeutic proteins concentrating specifically on the plant
plastid as a production system. The range of plant-produced
products discussed in this article does not include sub-unit
vaccines, secretory antibodies, or monoclonal antibodies,
these products have been specifically dealt with either in a
recent review or in other articles included in this issue [5-7].
It’s nearly 20 years since the first human protein (human
growth hormone) was expressed in plants [8]. The number of
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human therapeutic proteins that have been expressed in
plants via nuclear transformation has grown considerably
since then (Table 1). These studies have demonstrated
important points of principle relating to protein expression
levels [12, 14, 17, 28, 36, 37], protein processing [9, 24, 27,
35], protein complex assembly [29, 43], protein glycosyla-
tion [13] and protein stability [19, 22, 39, 41] that are
achievable in plant based systems. Clearly plant based
expression systems have been shown to work, many times
over. However, even after almost 20 years in development,
human therapeutic protein production in plants can hardly be
viewed as competing in a significant way with microbial
systems. Indeed, very few recombinant proteins of any type
have been produced in plants on a commercial scale (avidin,
β-glucuronidase, trypsin) [45, 46, 36].
Several factors have contributed to the delay in exploit-
ing the potential of plants as expression systems for
producing therapeutic proteins. One major factor is the low
level of protein expression that is generally obtained with
genes that are targeted to the nucleus. Typical protein
expression levels have been well below the 1% total soluble
protein (TSP) levels that have been used to compute the
impressive cost estimates proposed for the production of
plant based proteins [47]. This is not to imply that expression
levels cannot be increased to levels that are economically
viable. Several strategies have been adopted to increase
recombinant protein production levels including the use of
strong inducible or seed specific promoters as well as sub-
cellular targeting of recombinant proteins [48]. Another
successful strategy has been to backcross selected lines with
elite germplasms bred to maximize agronomic characteristics
[36, 45].
A second key factor that has hindered the adoption of
plant based expression systems, particularly in Europe,
relates to the “Catch 22” that is presented when large field-
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Table 1. Human Therapeutic Proteins Expressed in the Plant Nucleus
Protein
Glycosylation
state
Host plant
Targeted
genome
Therapy
Expression
levels a
Refsb
Hormones:
Human growth hormone NG Tobacco Nuclear Hypopituitary dwarfism 0.16 % TSP [9]
Calcitonin NG Potato Nuclear Osteoporosis 0.02% TSP [10]
Enkephalins NG
Arabidopsis
Oilseed
Nuclear Antihyperanalgesic 0.1% seed P [11]
Growth factors:
Epidermal growth factor G Tobacco Nuclear Wound repair 0.11% TSP [12]
Human intrinsic factor G Arabidopsis Nuclear Pernicious Anaemia 70mg/kg WW [13]
Human insulin-like growth
factor (IGF-1)
NG
Tobacco
Rice
Nuclear
Diabetes
Osteoporosis
0.037% TP [14]
Erythropoietin G Tobacco Nuclear Anaemia <0.01% TSP [15]
Cytokines:
Interleukin-2,-10,-12,-13,-18 NG Potato
Tobacco
Nuclear Inflammation 0.05% TSP [16-20]
Tumour necrosis factor α G Potato Nuclear Anticoagulant 15µg/g FW [21]
Granulocyte-macrophage
colony-stimulating factor
G
Tobacco
Rice
Nuclear
Neutropenia
Aplastic anemia
0.03% TSP
[22]
[23]
Interferon α G Potato Nuclear Antiviral agent 3029U/g FW [24]
Interferon β G Tobacco Nuclear Antiviral agent <0.01% FW [15, 25]
Interferon γ NG/G Tobacco Nuclear
Rheumatoid arthritis
Antiviral agent
0.001% TSP [26]
Blood proteins:
Serum albumin NG
Tobacco
Potato
Nuclear
Liver cirrhosis
Burns
0.2% TSP
[27]
[28]
Hemoglobin α, β NG/G Tobacco Nuclear Blood substitute 0.05% TP [29]
Hirudin NG Canola Nuclear Anticoagulant 13000 U/mg [30]
Protein C G Tobacco Nuclear Anticoagulant <0.01% TSP [15, 31]
α1-antitrypsin G Rice Nuclear
Emphysema
Cystic fibrosis
3.2 mg/g DW [32]
Protein/peptide inhibitors:
Aprotinin NG Maize Nuclear Trypsin inhibitor 0.069% seed SP [33]
Angiotensin-converting enzyme G
Tobacco
Tomato
Nuclear Hypertension not reported [34]
α-trichosanthin NG Tobacco Nuclear HIV therapy 2.7% TSP [35]
Enzymes:
Trypsin NG Maize Nuclear Digestive insufficiency 3.3% TSP [36]
Glutamic acid decarboxylase 65 NG Tobacco Nuclear Type 1 Diabetes 0.19% TSP [37]
Glucocerebrosidase G Tobacco Nuclear Gaucher disease 0.001% TSP [38]
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(Table 1) contd….
Protein
Glycosylation
state
Host plant
Targeted
genome
Therapy
Expression
levels a
Refsb
Acetylcholinesterase NG/G Tomato Nuclear
Organophosphate
poisoning
250nmolmin-
1mgprotein-1
[39]
Human-secreted alkaline phosphatase G Tobacco Nuclear Hypophosphatasia 3.0% TSP [40]
Gastric lipase G Tobacco Nuclear Pancreatic insufficiency 7% AEP [41]
Adenosine deaminase G Maize Nuclear Immuno-deficiency disorder not reported [42]
Biopolymers:
Collagen G Tobacco Nuclear Tissue reconstruction 30 mg/kg [43]
Elastin NG
Potato
Tobacco
Nuclear Tissue reconstruction 80 mg/kg [44]
  aOnly the highest available expression levels for each protein or class of protein are given
 bIn some cases only reviews that cite original citations are provided
scale production of recombinant proteins in plants is
considered. One of the advantages offered by the technology
is the potential for cheap and easy scale-up of plant based
protein production in field-scale conditions, indeed it is the
scale-up potential that makes the technology economically
viable. Unfortunately it is the perceived human and
environmental risks associated with field-scale production
that is the main disadvantage of the technology. Perceived
risks include the possible spread of transgenes by seed or
pollen dispersal, the potential for generating super-weeds or
super-pests, the possibility of food chain contamination
and/or human allergen exposure, the possibility of toxicity to
non-target organisms. Several strategies can be adopted to
minimize these risks including physical isolation and several
genetic containment strategies. Two recent reviews have
discussed the risk aspects associated with producing
recombinant proteins in plants and the strategies that might
be employed to assess and minimize these risks [49, 50].
However, an alternative strategy that can address the
issue of increasing levels of protein expression and can also
achieve a certain level of genetic containment is to bypass
the nucleus and instead target transgenes for expression in
the plant plastid genome.
PLANT PLASTIDS
Plastids are one of the three genetic compartments found
in plant cells (plastid, nucleus, mitochondrion). Like
mitochondria, plastids are thought to have evolved from a
bacterial progenitor (cyanobacterial-like) that entered into a
symbiotic relationship with a proto-eukaryotic cell [51].
“Plastid” is a general term that in fact describes several
organelle types that are derived from undifferentiated
proplastids found in the dividing cells of plant meristems
[52]. The complement of plastid types found in any plant is
organ and cell dependent and includes chloroplasts (leaves),
chromoplasts (fruits and flowers), leucoplasts (petals),
amyloplasts (seeds and tubers), and elaioplasts (fat/oil
storage organs). Since all plastid types share a common
developmental origin all plastid types in a given plant
species contain the same plastid genome. In general, plant
plastid genomes can be mapped as a single circular molecule
and plastid genomes typically range in size from 120 to 190-
kb depending on the plant species [53]. A major structural
feature of plastid genomes is the presence of a large inverted
repeat (IR) region that divides the molecule into two single
copy regions (large and small single copy regions); sequence
identity across the IR region is maintained by frequent inter-
and intra-molecular recombination. The number of plastids
per cell is also cell-type and cell-size dependent; leaf cells
are thought to contain the greatest number of plastids (up to
100 chloroplasts/cell). Each chloroplast can contain up to
100 copies of the plastid genome, thus, plant cells, and leaf
cells in particular, may contain up to 10,000 copies of its
plastid genome. Plastid inheritance occurs in a non-
Mendelian fashion and typically in flowering plants the
plastid is inherited through the maternal lineage and is not
transmitted via pollen [54].
Thus, plastids offer several obvious advantages over the
plant nucleus for transgene expression:
1. An active endogenous recombination system that allows
for targeted integration of transgenes via homologous
recombination. This eliminates concerns over position
effects on endogenous and transgene-expression and
ensures reproducible levels of transgene expression.
2. The high ploidy level of plastid genomes ensures mas-
sive gene amplification after integration leading to
potentially high levels of recombinant protein accumu-
lation.
3. The bacterial-like nature of plastids allows for multiple
transgenes to be stacked into operon-like expression
casettes that are recognised by the plastid transcriptional
and translational machinery.
4. Maternal inheritance eliminates the risk of genetic
pollution via the spread of pollen from plastid trans-
formed plants.
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HUMAN THERAPEUTIC PROTEINS EXPRESSED IN
PLASTIDS
The range of human therapeutic proteins (non-vaccine,
non-antibody) that have been expressed in plant plastids is
still quite limited (Table 2). One of the major drawbacks of
the plastid expression system is that plastids, like their
bacterial relatives, have no capacity for protein glycosyla-
tion. Thus, proteins that require glycosylation before they
can become biologically active are not suitable candidates
for plastid based expression. However, those proteins that
have been expressed in the plastid highlight the potential of
the system from several perspectives: 1) the levels of protein
expression that can be obtained; 2) the protein processing
capacity of the plastid system; 3) the protein purification
strategies that can be used to recover plastid produced
proteins; 4) the potential for inducible gene expression in the
plastid and 5) the potential for edible plastid-based protein
therapies.
Human Growth Hormone Somatotropin
Human growth hormone somatotropin (hST) was one of
the first recombinant human therapeutic proteins produced in
bacteria [60] and also the first human protein to be expressed
in plants [8]. Somatotropin is a small, non-glycosylated,
protein that is secreted by the pituitary gland and requires the
formation of two disulfide bonds for biological activity. The
primary use of hST is to treat hypopituitary dwarfism in
children but it may also have additional uses in the treatment
of a range of other conditions including Turner syndrome,
chronic renal failure, HIV wasting syndrome and age related
physical decline in general [61]. hST has been expressed
from the plant nucleus in a variety of contexts – as a nopa-
line synthase-hGT fusion protein [8], as a transit peptide-
protein fusion that directs the protein to the chloroplast [55],
as a protein targeted through the endoplasmic reticulum to
the secretory pathway [55] and as a protein directed to
accumulate in seeds [9]. The maximum level of protein
accumulated from these nuclear constructs was 0.16% TSP
[9]. In contrast, plastid based expression of hST in tobacco
chloroplasts has achieved 10-300 times higher protein
expression levels depending on the gene construction used
[55]. The highest level of plastid-based hST protein
expression (7% TSP) was achieved using a chimeric
ubiquitin-hGH gene construct under the control of the strong
constitutive chloroplast ribosomal RNA operon promoter
(Prrn) and containing a bacteriophage T7 gene 10 ribosome
binding site [55]. Despite the fact that plastids have no
apparent endogenous ubiquitin protease activity up to 80%
of the total ubiquitin-hGH fusion protein produced was
processed downstream of the ubiquitin C-terminal amino
acid. The extent of protein processing was dependent on the
protein extraction conditions used and presumably was
carried out by non-plastid, plant ubiquitin proteases during
the extraction process. In addition to proteolytic removal of
the ubiquitin moiety most of the processed hGT protein
Table 2. Human Therapeutic Proteins Expressed in the Plastid
Protein
Glycosylation
state
Host plant
Targeted
genome
Therapy
Expression
levels
Refs
Hormones:
Human growth hormone NG Tobacco Chloroplast
Hypopituitary dwarfism
Turner syndrome
7.0% TSP [55]
Cytokines:
Interferon γ NG/G Tobacco Chloroplast
Rheumatoid arthritis
 Hepatitis B
Cancer
6% TSP [26]
Blood proteins:
Serum albumin NG Tobacco Chloroplast
Liver cirrhosis
Burns
11.1%TSP [56]
Hemoglobin α, β NG Tobacco Chloroplast
Blood substitute
Ischemia
__ [57]
Biopolymers:
Elastin NG Tobacco Chloroplast  Tissue reconstruction not reported
[58]
Antimicrobial peptides:
Magainins (MSI-99) NG Tobacco Chloroplast
 Anti-cancer agent
Wound-healing
not reported [59]
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underwent an additional proteolytic cleavage that removed
the N-terminal amino acid of the hGT protein. Removal of
the N-terminal amino acid was obtained with either an N-
terminal methionine or N-terminal phenylalanine suggesting
either that N-terminal amino acid removal is an additional
feature of the ubiquitin processing step or that removal was
mediated by secondary aminopeptidase activity. Despite the
fact that no known plastid-encoded proteins contain disulfide
bonds the plastid produced properly folded hST that
exhibited proper disulfide bond formation and was
biologically active.
Human Serum Albumin
Human serum albumin (HSA) is the major protein
component in blood serum and is used in the treatment of a
wide range of medical conditions including large-scale
plasma infusions for burn victims and patients who have lost
large volumes of blood [62]. The demand for HSA is huge
and typically more than 10g of protein is required per
administered dose. The annual world requirement for this
blood protein (500 tons) is estimated to have a market value
of more than $1.5 billion [56]. HSA is a secreted prepro-
protein and proper folding of the protein requires the
formation of 17 disulphide bonds. Commercial HSA is still
obtained from human plasma despite the associated medical
risks involved such as viral (HIV, hepatitis) and prion
contamination. Recombinant HSA has been produced in a
range of microbial expression systems, including E. coli
[63], Saccharomyces cerevisiae [64] and Pichia pastoris [65]
however, none of these systems has become commercially
feasible mainly because the protein is susceptible to
proteolytic degradation and is expensive to purify. Attempts
to express HSA in the plant nuclear genome have achieved
protein expression levels of up to 0.02% TSP in shoots and
leaves (tobacco and potato) [27] and 0.2% TSP in potato
tubers [28]. These expression levels are also not sufficient to
make plant based nuclear expression of the protein a
commercially viable option. Pharmaceutical industry
estimates have suggested that plant based expression levels
of at least 0.1mg HSA/g fresh weight are needed in order for
the system to be considered cost-effective [28]. HSA
expression and subsequent protein extraction from tobacco
plastids, however, has surpassed these industry-required
estimates for cost effective production. Expression of the
mature HSA coding sequence under the control of the
chloroplast, light regulated, psbA gene expression signals
generated protein expression levels of between 7.2% and
11.1% TSP depending on the light conditions used to grow
the transformed plants [56]. Plastid produced HSA
accumulated in large inclusion bodies that significantly
protected the protein from proteolysis and facilitated the
purification of HSA from transformed plant tissue. Properly
folded HSA was recovered from the plastids after
solubilization of the inclusion bodies and subsequent in vitro
protein refolding. Although the final amount of folded HSA
recovered was only 20% of the initial amount of HSA
produced in tobacco leaves, this represents a recovery of
approximately 0.25mg HSA/g fresh weight, more than
double the amount estimated by industry to be required for
cost effective production.
Human Interferon Gamma
Although maximizing protein expression levels in
plastids is important for the development of the system as a
viable option for human therapeutic protein production,
ultimately the success of the system will also depend on the
development of efficient and cost effective protein
purification strategies. Purifying recombinant proteins from
plants is potentially more expensive compared to purification
of the same product from microbial systems, mainly due to
the low ratio of recombinant protein to total biomass of plant
material [15, 34]. Thus, strategies that minimise downstream
processing costs will make plant-based expression systems
more cost effective and economically viable.
Leelavathi and Reddy (2003) have developed an efficient
strategy to both produce and purify recombinant human
interferon gamma (IFN-g) from plant plastids [26]. IFN-g
has been used in a wide range of human therapies, as an
antiproliferative (treatment for several cancers), an
immunoregulator (treatment for rheumatoid arthritis) and as
an antiviral agent (treatment for hepatitis B virus infection).
The human ifnG gene was transformed into the tobacco
nuclear and plastid genomes and was initially expressed as
an independent IFN-g protein [26]. The highest level of IFN-
g protein expression obtained from nuclear transformation
was 0.001% TSP. The ifnG coding region was introduced
into the tobacco plastid genome under the control of the rice
psbA gene 5’ and 3’ expression signals. Expression of IFN-g
from this construct in transplastomic tobacco plants was only
0.1% TSP (although still 100 fold higher than levels obtained
with nuclear expression). A similar construct containing the
reporter gene uidA (GUS), under the control of the same
expression signals (rice psbA), introduced into the tobacco
plastid genome generated transformed plants with GUS
expression levels 30 fold higher (3% TSP). Pulse labeling
experiments indicated that the low level of IFN-g expression
was due to significant proteolysis of the INF-g protein (half-
life 4-6 hours) compared to GUS (half-life 48 hours). In
order to boost INF-g expression levels a uidA:ifnG gene
fusion, containing a HIS-tag at the 5’end of the uidA gene
and a factor Xa recognition at the 5’ end of the ifnG gene,
was constructed and introduced into the tobacco plastid
genome. Plants transformed with the fusion construct
expressed GUS:IFN-g fusion protein to a level of 6% TSP
(60 fold higher than IFN-g alone). Pulse-labeling
experiments indicated that the GUS:IFN-g had a half-life
similar to GUS. The fusion protein was purified using HIS-
tag based affinity chromatography and more than 75% of the
total protein produced in tobacco leaves was subsequently
recovered. The INF-g was cleaved from the purified
GUS:IFN-g fusion by factor Xa digestion. The purified IFN-
g was bioactive and gave complete protection to human lung
carcinomas (A549 cells) against EMC viral infection. Unlike
the uncontrolled cleavage of hST from an ubiquitin-hST
fusion protein that occurred during the protein extraction
process (30-80% cleavage efficiency depending on
extraction method [55]) the GUS:IFN-g fusion protein
remained intact until it was processed by factor Xa giving
total control over the cleavage process. Theoretically this
system, or a similar processing system, could be used to
stabilize and purify any recombinant protein produced in the
plant plastid.
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Hemoglobin
Demonstrating that plants have the potential to be used as
efficient bioreactors to produce human therapeutic proteins is
one issue. Actually translating this potential into fields of
plants that are producing human drug therapies is quite
another. One of the obvious potential dangers is the effect
that pharmaceutical proteins could have on populations of
soil microorganisms or insects and other animals that might
feed on the plants [49]. One way to reduce the environmental
risks posed by plant based pharmaceutical proteins is to
restrict transgene expression, for example, to limit the
expression of recombinant proteins to post-harvest tissue
after the crop has been removed from field conditions.
McBride et al (1994) first demonstrated controlled
expression of plastid transgenes using a nuclear encoded,
plastid-targeted, T7 RNA polymerase [66]. Magee et al.
(2004) adopted this system in an attempt to develop an
inducible plastid expression system for α- and β- subunits of
human adult hemoglobin [57].
Developing recombinant sources of human blood
substitutes could significantly alleviate current concerns
about conventional blood transfusion therapy. Recombinant
hemoglobin has been produced in bacteria, yeasts, and in
transgenic animals and plants [67, 29]. Co-expression of the
α- and β- chain of human hemoglobin in the nucleus of
transgenic tobacco plants expressed functional tetrameric
hemoglobin to levels of 0.05% TSP [29]. A di-cistronic
expression cassette (Hb) containing the human hemoglobin
α- and β-subunit genes, under the transcriptional control of a
phage T7 promoter, was introduced into the tobacco plastid
genome [57]. Under normal conditions the plastid
transcriptional machinery does not recognize this phage T7
promoter [66]. One of the plastid-transformed lines was
crossed with a nuclear transformed line containing a salicylic
acid-inducible plastid-targeted T7 RNA polymerase. Levels
of Hb transcripts were assessed in detached leaves from
progeny plants treated with 2mM salicylic acid solution or
progeny plants directly sprayed with the salicylic acid
solution. Although significant levels of Hb transcript were
detected in untreated leaf tissue, transcript levels were higher
in the salicylic acid treated leaves (both detached and
attached leaves). However, despite high levels of Hb
transcription no recombinant hemoglobin protein was
detected in the dual plastid/nuclear transformed lines. Lack
of protein expression is most likely due to protein instability
in the plastid [57]. Modifying the gene construct and
incorporating sequences that are known to enhance protein
stability (5’ UTR and N-terminal fusion sequences) could
enhance hemoglobin protein expression levels in the plastid
[68]. Hb transcription in the absence of induction was likely
due to a basal level of the inducible promoter activity and the
system could be improved by using alternative promoters
that offer tighter control over gene expression. Several other
chemically inducible systems are available in plants that
could be more effective than the salicylic acid inducible
promoter and could be used to regulate the expression of
plastid transgenes [69]. Although this current system is not
perfect, it clearly demonstrates the potential for inducible
gene expression in plant plastids and the possibility for post-
harvest recombinant protein production in a plastid based
expression system.
Therapeutic Synthetic Peptides
Magainin-Like Peptides
Magainins are short (20 to 26 amino acids) antimicrobial
peptides (AMPs) that are found in plants and animals
ranging from fruit flies to humans [70]. They constitute part
of the innate defense system that curbs microbial flora and
fights pathogen attack [71, 72]. These proteins are α-helical
peptide ionophores that rapidly dissipate ion gradients across
membranes resulting in cell lysis. Magainins have been
shown to lyse bacteria, hematopoietic tumor and solid target
cells, viruses, fungi and sperm cells [71-73]. Magainins, and
their analogues, have therapeutic potential as broad-spectrum
topical agents, as anti-microbial agents to combat antibiotic-
resistant “superbugs”, as anti-cancer agents, and as a
contraceptive with combined anti-viral, anti-bacterial and
anti-fungal activity. The peptide MSI-99, an analogue of
magainin 2 isolated from Xenopus laevis [74] was introduced
into the tobacco plastid genome [59]. The transformed plants
grew normally and showed no apparent morphological
abnormalities. Although levels of MSI-99 protein expression
were not directly assessed, the transplastomic plants
exhibited significant in planta antifungal activity against the
plant pathogens Pseudomonas syringae pv tabaci and
Colletotrichum destructivum . In addition, leaf extracts from
transplastomic plants significantly inhibited the growth of
pre-germinated spores of three fungal species, Aspergillus
flavus, Fusarium moniliforme and Verticillium dahliae [59].
Although these experiments demonstrate an obvious
agricultural use for magainin-type AMPs, the fact that MSI-
99 can be expressed in tobacco plastids without any harmful
effects on plants or plastids suggests that the system could
also be used to express this class of peptide for human
therapeutic use. One of the disadvantages of α-helical AMPs
is the instability of the proteins that makes them unsuitable
for oral delivery [75]. However, plastid-based expression of
unstable peptides in edible plant species could provide both a
means of production and delivery of these peptides to the
human gut. Both the plant cell wall and the plastid might
offer a degree of controlled release of the peptide in the gut
that could significantly enhance its therapeutic capability. A
plastid transformation system is now available for tomato
[76], a species that produces edible tissue that can be
consumed without cooking. Tomato, and other plant species
that can be consumed raw, would be excellent systems in
which to develop plastid-based expression of AMPs and
other therapeutic proteins that could be delivered orally as
edible therapies.
Elastin-Like Polymers
Elastin is one of the strongest natural fibers commonly
found in ligaments and arterial cell walls. Elastins are
polymeric proteins composed of repeated sequences of basic
amino acids usually Valine, Glycine and Proline. Bovine
elastin has the sequence (Val-Pro-Gly-Val-Gly)11 without
any amino acid deviation. Synthetic elastin-like polymers
have been synthesized both chemically and by recombinant
DNA technology for both medical and non-medical
applications. The polymers have medical relevance because
they are extremely biocompatible molecules that are ignored
by the immune system and elicit no immune reaction.
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Elastin-like polymers are used for tissue reconstruction, to
prevent post-surgical adhesions and scars, for drug delivery,
as biosensors and as coatings for catheters and drainage
tubes [77, 78, 79]. Non-medical applications are as
transducers, thermoplastics with designable half-lives, food
additives and cosmetics. A synthetic polymer gene (EG121),
encoding the polymeric protein (GVGVP) 121 was engineered
for expression in E.coli and generated extremely high levels
of polymer protein production [80]. The EG121gene was
subsequently introduced into both the tobacco nuclear and
plastid genomes in the expectation that plants might generate
polymer protein at a lower cost and at a higher volume than a
microbial production system [81, 82, 58]. Surprisingly,
despite the fact that polymer transcript levels were up to 100
fold higher in plastid transformants, the level of polymer
protein expression was lower than in the highest expressing
nuclear transformed line [58]. Since the synthetic polymer
contains no known protease cleavage sites the low level of
polymer protein expression in plastids is thought to be due to
the unusual composition of the protein (40% glycine, 40%
valine and 20% proline) [58]. Although the amino acids
valine and proline can be synthesized by plastids there is no
plastid-based biosynthetic pathway for glycine and this
amino acid has to be imported by the plastid. Thus, glycine
availability could be a limiting factor for the low level of
(GVGVP)121 protein expression in plastids. In addition,
availability of tRNAs could also be a contributing factor.
The tobacco plastid genome encodes a set of 30 tRNA
molecules that is sufficient to translate all 61 possible codons
allowing for wobble base pairing in codon-anticodon
recognition. However, the tobacco plastid genome has only a
single gene that specifies tRNA-proline (trnP-UGG), thus,
availability of tRNA-pro could be a limiting factor for
plastid based production of this highly repetitive polymer
protein [58]. Reducing the size of the polymeric protein
could increase polymer protein expression levels in the
plastid. Polymer size does not alter the useful properties of
elastin-like proteins and most medical applications are
carried out with much smaller molecules [83]. Attempts are
being made to express a smaller synthetic polymer gene
encoding the polymeric protein (GVGVP) 20 to see if this
expresses better in the plant plastid [58].
CONSIDERATIONS FOR PLASTID-BASED PROTEIN
EXPRESSION
Host Species Options
Until recently the only choice of host species for plastid
transformation was the single-cell green alga Chlamydo-
monas reinhardtii or the land plant Nicotiana tabacum
(tobacco). Although the Chlamydomonas plastid was the first
plastid to be stably transformed [84], very little attention has
been given to the development of this system for the
production of recombinant proteins. This could be about to
change and a recent review has discussed future prospects
for recombinant protein production in Chlamydomonas [85].
By far the most popular plastid-based expression system in
use is tobacco, and biolistic-mediated plastid transformation
of tobacco is now routine in many labs [86]. Transplastomic
tobacco plants can be generated quickly (primary trans-
formed shoots can be regenerated in as little as three weeks)
and at a relatively high frequency (one event per bombarded
plate; [86]). A range of versatile vectors and expression
cassettes are available that are capable of generating high
levels of recombinant protein expression in tobacco plastids
[87]. Tobacco can generate high yields of biomass, and since
tobacco is a non-food crop for both humans and livestock,
the risk of contaminating feed and human food chains with
transgenic material is minimized. The disadvantage of the
tobacco system is the high content of nicotine and other toxic
alkaloids that have to be completely removed during protein
purification steps and which add to downstream processing
costs [88, 48].
After a slow start, plastid transformation is finally being
extended to include a range of other plant species (Table 3).
However, plastid transformation in these species is still
considerably more laborious and time-consuming than in
tobacco. Modifying tissue culture conditions and choice of
cultivar could significantly improve transformation
efficiency in these species. The availability of a plastid
transformation system for tomato, a crop plant that can be
eaten raw by humans, could reduce downstream processing
costs and will now allow researchers to explore the
possibility of edible, plastid-produced, drug therapies.
Table 3. Plant Species in Which Plastid Transformation has been Achieved
Species Transformation Method Transformed genome state Plant regeneration Ref
Tobacco Biolistic, protoplast Homoplasmic Yes [86, 89]
Potato Biolistic Homoplasmic Yes [90]
Tomato Biolistic Homoplasmic Yes [76]
Arabidopsis Biolistic Homoplasmic Yes [91]
Lesquerella Biolistic Homoplasmic Yes [92]
Oilseed rape Biolistic Heteroplasmic Yes [93]
Rice Biolistic Heteroplasmic Yes [94]
Soybean Biolistic Heteroplasmic No [95]
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Vector Design
Plastid transformation vectors include plastid DNA-
targeting regions that flank the expression cassette to be
introduced into the plastid genome. Recombination between
the vector target sequences and the homologous sequences
on the plastid genome allows for directed integration of the
transgene expression cassette. Transgenes have been
introduced at up to 14 locations distributed throughout the
plastid genome [87]. By far the most extensive set of
transformation vectors have been designed for tobacco
plastid transformation [87]. Some of the most commonly
used tobacco vectors target both the large single copy region
(pZS range – rbcL-accD; and pRB range – trnM-trnG) and
the inverted repeat region of the plastid genome (pPRV
range – trnV-rps12/7 and pLD range-trnI-trnA). There is no
evidence that the choice of target site can affect protein
expression levels, however, the choice of vector target
sequences can sometimes affect plastid transformation
frequency [76]. Vector target sequences have no special
requirements, other than that they are homologous to the
chosen target site, and generally include 1-2 kb of target
DNA [68]. Tobacco vectors were used for plastid
transformation in the related Solanceous species (potato and
tomato) but the transformation frequency in these species
was much lower than in tobacco. This suggests that chloro-
plast genomes can tolerate a certain level of mismatched
recombination between homologous (though not identical)
DNA sequences from closely related species. Plastid
transformation in non-Solanaceous species have generally
used vectors that are designed based on host genome target
sites [91, 93-95].
Expression Cassette Design
Levels of recombinant protein produced in plastids is
very much dependent on expression cassette design. Maliga
(2003) recently summarized the expression cassette
constructs that have demonstrated high levels of protein
expression in plastids [68]. Expression cassettes generally
include a strong promoter to ensure high levels of
transcription of the transgene and most cassettes use the
strong plastid rRNA operon (rrn) promoter. However,
transcription is not the rate-limiting step in plastid gene
expression. Rather, the level of protein expression in plastids
is much more dependent on post-transcriptional processes
such as transcript stability and translational initiation and
elongation on polyribosomes [68, 96]. The 5’ and 3’
untranslated regions (UTRs) from various sources of plastid
genes have been incorporated into expression cassettes to
stabilize transgene transcripts (3’ UTRs) and to enhance
translation initiation rates from these transcripts (5’ UTRs)
[68]. Post-translational processes can also significantly affect
protein expression levels in the plastid. Some recombinant
proteins are more susceptible to proteolysis in the plastid
than others, and protein instability does not appear to be
source dependent (human serum albumin is stable in
plastids, human IFN-g and hemoglobin are not [56, 26, 57]).
However, both heterologous protein fusions (ubiquitin and
GUS) [55, 26] and fusions with the amino-termini of various
source plastid proteins (RBCL and ATPB) can greatly
enhance recombinant protein stability in plastids [68].
THE FUTURE FOR PLASTID-BASED PRODUCTION
OF HUMAN THERAPEUTIC PROTEINS
Clearly, the plastid has huge potential for commercial
scale production of human therapeutic proteins in plants and
offers several advantages over a nuclear expression system
(Table 4). The level of protein expression that can be
obtained in plastids is 100s of times higher than that
generally obtained via the nucleus. Although the expression
levels achieved for hST (7% TSP), HSA (11.1% TSP) and
IFN-g (6% TSP) have been very impressive they are still
Table 4. Comparison of Plant-Based Nuclear and Plastid Expression Systems
Nuclear expression Plastid expression
Protein expression levels Low/moderate High
Protein processing Yes Possible
Disulfide bond formation Yes Yes
Protein glycosylation Yes No
Inducible gene expression Yes Possible
Transgene silencing Yes No
Multiple transgene stacking Genetic crossing Polycistronic constructs
Scale up potential Large Large
Development time High Very high
Species range Most species Limited
Mode of inheritance Mendelian Maternal (mostly)
Environmental concerns High Medium
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considerably below the level of recombinant protein that has
been obtained for the Bacillus thuringiensis cry2A crystal
protein (45.3% TSP) in plant plastids [97]. This suggests that
levels of therapeutic protein expression in this system could
still be significantly improved in the future, possibly by
modifying gene regulatory and/or protein stabilizing
sequences. Plastids can produce human proteins that are
properly folded and are biologically active. Even proteins
that require a significant number of disulphide bonds for
proper folding are folded correctly in the plant plastid (HSA
– 17 disulphide bonds; [56]). Both ubiquitin and factor Xa
mediated processing of plastid-produced fusion proteins can
generate mature proteins with non-methionine N-termini
similar to many processed human proteins. The possibility of
an inducible plastid gene expression system could lead to
regulated plastid gene expression and might even allow for
high levels of recombinant protein production in the plastids
of post-harvest plant tissue. Plastid-based protein production
in edible plant systems could minimize downstream protein
processing costs and also raises the possibility of future
“edible” protein therapies.
The disadvantages of the system are the lack of a glyco-
sylation mechanism and the fact that, so far, there appear to
be no hard and fast rules that can be applied to predict
protein stability in the plastid. Pre-screening of plastid trans-
gene expression cassettes in E.coli is not a reliable predictor
of plastid expression levels [57]. Achieving maximum levels
of human recombinant proteins in plastids still necessitates
that transgenes are introduced into a range of cassettes that
utilize different types of translational control. Thus, signifi-
cant time and effort is still required to obtain the constructs
that will generate a stable protein that can accumulate to high
levels in the plastid. Protein stability was also a significant
problem in the early days of bacterial expression systems
and this was more or less solved by co-expressing chaperone
proteins and reducing bacterial proteolytic capability. No
doubt, general strategies to stabilize protein production can
also be developed to increase the effectiveness of plastid
expression systems in the future.
The number of human therapeutic proteins that have been
expressed in plastids is still small. However, the system has
obvious potential that could be applied to express a much
wider range of therapeutic molecules. Several of the
therapeutic proteins that have already been expressed in the
plant nucleus (Table 1) could be good future targets for
enhanced plastid-based expression. Proteins that have to be
glycosylated before they become biologically active are not
suitable candidates and plant-based expression of these
proteins will continue to focus on the nucleus using various
strategies to maximize protein expression levels. However,
not all glycoproteins need to be glycosylated to be
biologically active. For example, human IFN-g is glycosyla-
ted, semi-glycosylated and non-glycosylated in vivo [98] and
non-glycosylated recombinant protein produced in E. coli
and in the plastid is bioactive [99, 26]. Human acetylchol-
inesterase is still enzymatic in the non-glycosylated state
although glycosylation does appear to be important for
enzyme stability [39]. Thus, glycosylation alone is not a
good criterion by which to judge the suitability of a protein
for plastid-based expression. Several of the human
therapeutic proteins listed in Table 1 are not glycosylated in
vivo and are more obvious potential targets for plastid-based
expression. These potential targets include a broad range of
therapeutic proteins including hormones (proinsulin), growth
factors (insulin-like growth factor), blood proteins (hemo-
globin, hirudin), cytokines (interleukins, tumor necrosis
factor), enzymes (trypsin, glutamic acid decarboxylase) and
no doubt many other proteins.
The jury is still out with respect to the future of large
field-scale production of human therapeutic proteins in
plants. Despite the obvious potential of plant-based protein
expression systems their future relevance as bioreactors for
biopharmaceutical proteins will ultimately depend on the
level of containment (tissue, seed, pollen) that can be
demonstrated within the system. Stringent regulatory
guidelines and controls will have to be determined, and
established, that address all aspects of consumer and
environmental concerns before field-scale production of
plant based human therapeutic proteins becomes a reality.
The issues relating to field scale production will continue to
be debated and are likely to become much more contentious
if the levels of protein expression generally achieved in
plants can make the technology significantly more economi-
cally viable than other production systems. Ultimately the
choice of protein production system, plant V non-plant or
plant nucleus V plant plastid, will depend on the balance
achieved between protein market value, development costs,
scale up potential and biosafety concerns. With respect to
choosing between the two plant-based production systems
(nucleus V plastid), the high level of protein expression
achievable in plastids could significantly reduce the level of
scale-up required to make plant based protein production
commercially feasible. Depending on the market value of the
protein, the level of protein expression that is achieved, and
the efficiency of downstream processing steps, it could be
possible to produce plastid-based therapeutic proteins on a
scale that could be accommodated in contained glasshouse
conditions and still be an economically viable option.
Growing plastid-transformed plants under contained
conditions and coupled with the level of biosafety conferred
by maternal inheritance of plastid transgenes, would go a
long way towards addressing many of the social and
environmental concerns relating to plant based production of
human therapeutic proteins.
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